Expression of CD30 and CD30L in Human Myeloid Hematopoietic Malignancies
| Diagnosis . | CD30 . | CD30L . | ||
|---|---|---|---|---|
| . | No. Positive/No. Tested . | % Stained Cells (range)* . | No. Positive/No. Tested . | % Stained Cells (range) . |
| AML | 4/67 | 22-26† | 40/67 | 23-92 |
| M0 | 0/3 | — | 1/3 | 23 |
| M1 | 2/16 | 22-26 | 7/16‡ | 24-38 |
| M2 | 0/6 | — | 1/6 | 24 |
| M3 | 0/7 | — | 4/7 | 35-43 |
| M4 | 2/17 | 23-25 | 13/17 | 35-72 |
| M5 | 0/16 | — | 14/16 | 48-92 |
| M6 | 0/1 | — | 0/1 | — |
| M7 | 0/1 | — | 0/1 | — |
| MBC | 0/5 | — | 4/5 | 25-35 |
| CML | 0/3 | — | 2/3 | 25-35 |
| PV | 0/1 | — | 1/1 | 28 |
| IM | 0/1 | — | 1/1 | 31 |
| Diagnosis . | CD30 . | CD30L . | ||
|---|---|---|---|---|
| . | No. Positive/No. Tested . | % Stained Cells (range)* . | No. Positive/No. Tested . | % Stained Cells (range) . |
| AML | 4/67 | 22-26† | 40/67 | 23-92 |
| M0 | 0/3 | — | 1/3 | 23 |
| M1 | 2/16 | 22-26 | 7/16‡ | 24-38 |
| M2 | 0/6 | — | 1/6 | 24 |
| M3 | 0/7 | — | 4/7 | 35-43 |
| M4 | 2/17 | 23-25 | 13/17 | 35-72 |
| M5 | 0/16 | — | 14/16 | 48-92 |
| M6 | 0/1 | — | 0/1 | — |
| M7 | 0/1 | — | 0/1 | — |
| MBC | 0/5 | — | 4/5 | 25-35 |
| CML | 0/3 | — | 2/3 | 25-35 |
| PV | 0/1 | — | 1/1 | 28 |
| IM | 0/1 | — | 1/1 | 31 |
CD30 and CD30L expression was evaluated by RT-PCR and immunofluorescence staining using the anti-CD30 MoAb M44 or the anti-CD30L MoAb M80.
Abbreviations: AML, acute myeloid leukemia; MBC, myeloid blast crisis of myeloproliferative disorders; CML, chronic myeloid leukemia; PV, polycythemia vera; IM, idiopathic myelofibrosis.
As evaluated by flow cytometry.
Figures refer to positive cases, ie, displaying more than 20% of stained cells in flow cytometry.
Two cases coexpressed CD30 as evaluated by both RT-PCR and flow cytometry.